Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience. Issue 9 (29th May 2021)

• Record Type: Journal Article
• Authors: Kisioglu, Savas Volkan; Demir, Ahmet Suat; Tufekci, Damla; Emur Gunay, Yasemin; Coskun, Hulya; Ucuncu, Ozge; Nuhoglu, Irfan; Kocak, Mustafa; Karakullukcu, Serdar; Ersoz, Halil Onder
• Is Part Of: International journal of clinical practice. Volume 75:Issue 9(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-29
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14377
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Aims: Insulin degludec/aspart (IDegAsp) and insulin glargine U300 (IGlarU300) have recently emerged as popular new‐generation insulin analogues. The aim of this real‐life study was to investigate the patient profiles in which IGlarU300 and IDegAsp were preferred and the insulin combinations after which each of them were mostly used and also to analyse the effect of these two insulin analogues on blood glucose regulation and hypoglycaemia. Materials and Methods: The retrospective study included 174 patients that were switched from basal insulin, basal‐bolus insulin, or premixed insulin to IGlarU300 or IDegAsp due to uncontrolled blood glucose levels or history of hypoglycaemia. Hypoglycaemia, body weight, body mass index (BMI), fasting plasma glucose (FPG) and HbA1c levels over 3‐month periods were evaluated for each patient. Results: There were 84 and 90 patients in the IGlarU300 and IDegAsp groups, respectively. Body weight was similar in both groups. Baseline FPG and HbA1c levels in the IGlarU300 and IDegAsp groups were 9.0%, 175.5 mg/dL and 9.4%, 193.5 mg/dL, respectively. A significant decrease was found in FPG and HbA1c levels in both groups (138.5, 7.8 vs 141.5, 8.2; P < .001 for all). Moreover, a significant weight gain was observed in both groups ( P < .05 for both). The prevalence of hypoglycaemia in both groups decreased significantly and consistently between months 1 and 9 ( P < .001). At month 12, although this decrease continued in the IGlarU300 group ( P = .013), no significant decrease was observed in the IDegAsp group ( P = .057). Conclusion: Both twice‐daily IDegAsp ± bolus insulin and IGlarU300 basal bolus insulin therapies are effective and safe treatment modalities.